Incretin Therapies Do Not Expand β-cell Mass or Alter Pancreatic Histology in Young Male Mice.

Incretin Therapies Do Not Expand β-cell Mass or Alter Pancreatic Histology in Young Male Mice. Endocrinology. 2017 Mar 08;: Authors: Cox AR, Lam CJ, Rankin MM, Rios JS, Chavez J, Bonnyman CW, King KB, Wells RA, Anthony D, Tu JX, Kim JJ, Li C, Kushner JA Abstract The impact of incretins upon pancreatic β-cell expansion remains extremely controversial. Multiple studies indicate that incretin-based therapies can increase β-cell proliferation, and incretins have been hypothesized to expand β-cell mass. However, considerable disagreement exists on whether incretins actually increase β-cell mass. Moreover, some reports indicate that incretins may cause metaplastic changes in pancreatic histology. To resolve these questions we treated a large cohort of mice with incretin-based therapies and carried out a rigorous analysis of β-cell turnover and pancreatic histology using high-throughput imaging.Young mice received exenatide via osmotic pump, des-fluoro-sitagliptin or glipizide compounded in diet for 2-weeks (short-term) on low fat diet (LFD), or 4.5-months (long-term) on LFD or high fat (HFD). Pancreata were quantified for β-cell turnover and mass. A independent pathologist examined H&E slides for gross anatomical and microscopic changes to exocrine pancreas.Short-term des-fluoro-sitagliptin increased serum insulin and induced modest β-cell proliferation but no change in β-cell mass. Long-term incretin therapy in HFD-fed mice r...
Source: Endocrinology - Category: Endocrinology Authors: Tags: Endocrinology Source Type: research